+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "CRISPR"

From
CRISPR Technology - Global Strategic Business Report - Product Thumbnail Image

CRISPR Technology - Global Strategic Business Report

  • Report
  • April 2024
  • 89 Pages
  • Global
From
CRISPR Technology Global Market Report 2024 - Product Thumbnail Image

CRISPR Technology Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
CRISPR and Cas Gene Global Market Report 2024 - Product Thumbnail Image

CRISPR and Cas Gene Global Market Report 2024

  • Report
  • March 2024
  • 175 Pages
  • Global
From
From
CRISPR therapies - Pipeline Insight, 2024 - Product Thumbnail Image

CRISPR therapies - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
From
From
Viral Vector Collaboration and Licensing Deals 2016-2023 - Product Thumbnail Image

Viral Vector Collaboration and Licensing Deals 2016-2023

  • Report
  • November 2023
  • 250 Pages
  • Global
From
From
From
Loading Indicator

The CRISPR market is a subset of the genomics market that focuses on the use of CRISPR-Cas9 technology for gene editing. CRISPR-Cas9 is a powerful tool that enables scientists to make precise changes to the genome of living organisms. This technology has been used to develop treatments for a variety of diseases, as well as to create new crops and livestock. CRISPR-Cas9 technology has also been used to create gene drives, which are designed to spread a desired trait through a population. The CRISPR market is highly competitive, with a number of companies offering products and services related to gene editing. These companies include Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, Caribou Biosciences, and ERS Genomics. These companies are developing a range of products, from gene editing tools to gene therapies, and are working to make CRISPR-Cas9 technology more accessible and affordable. Show Less Read more